Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process

Executive Summary

Former deputy commissioner will also likely push increased use of biomarkers and more flexibility in off-label communication, among other reforms.

You may also be interested in...



FDA Commissioner-Nominee Gottlieb Pressed More On Drug Development Than Industry Ties

Scott Gottlieb's industry connections were expected to be a major focus of his US Senate confirmation hearing. However, our analysis of the questions asked show drug development was the top priority.

'Repeal And Replace' Going Relatively Well For Pharma So Far

US White House game plan for repealing and replacing the Affordable Care Act includes a proposal for faster generic drug approvals but no direct government price controls.

Off-Label Wish List: Industry Groups Want US FDA's Guidances To Do More

Sponsors and payers question guidances' scope and potential audiences, and wonder if the agency couldn't just perform some retrospective audits of off-label communication to speed things up.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC098382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel